Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Valley Care Medical Center
mi
from
Pleasanton, CA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Valley Care Medical Center
mi
from
Pleasanton, CA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
University of California Davis Cancer Center
mi
from
Sacramento, CA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Doctors Medical Center - San Pablo Campus
mi
from
San Pablo, CA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Doctors Medical Center - San Pablo Campus
mi
from
San Pablo, CA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center at University of Colorado Health Sciences Center
mi
from
Aurora, CO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center at University of Colorado Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Denver Health Medical Center
mi
from
Denver, CO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Denver Health Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - Denver
mi
from
Denver, CO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - Denver
mi
from
Denver, CO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Montrose Memorial Hospital Cancer Center
mi
from
Montrose, CO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Montrose Memorial Hospital Cancer Center
mi
from
Montrose, CO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Exempla Lutheran Medical Center
mi
from
Wheat Ridge, CO
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Exempla Lutheran Medical Center
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Piedmont Hospital
mi
from
Atlanta, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Northside Hospital Cancer Center
mi
from
Atlanta, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Northside Hospital Cancer Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Saint Joseph's Hospital of Atlanta
mi
from
Atlanta, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Saint Joseph's Hospital of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Atlanta Regional
mi
from
Atlanta, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Atlanta Regional
mi
from
Atlanta, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
WellStar Cobb Hospital
mi
from
Austell, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
WellStar Cobb Hospital
mi
from
Austell, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Charles B. Eberhart Cancer Center at DeKalb Medical Center
mi
from
Decatur, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Charles B. Eberhart Cancer Center at DeKalb Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Northeast Georgia Medical Center
mi
from
Gainesville, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Gwinnett Medical Center
mi
from
Lawrenceville, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Gwinnett Medical Center
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Kennestone Cancer Center at Wellstar Kennestone Hospital
mi
from
Marietta, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Kennestone Cancer Center at Wellstar Kennestone Hospital
mi
from
Marietta, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Southern Regional Medical Center
mi
from
Riverdale, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Southern Regional Medical Center
mi
from
Riverdale, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
mi
from
Savannah, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Pearlman Comprehensive Cancer Center at South Georgia Medical Center
mi
from
Valdosta, GA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Pearlman Comprehensive Cancer Center at South Georgia Medical Center
mi
from
Valdosta, GA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Sherman Hospital
mi
from
Elgin, IL
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Sherman Hospital
mi
from
Elgin, IL
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Center at Memorial Medical Center
mi
from
Springfield, IL
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Center at Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Reid Hospital & Health Care Services, Incorporated
mi
from
Richmond, IN
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Reid Hospital & Health Care Services, Incorporated
mi
from
Richmond, IN
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - Kansas City
mi
from
Kansas City, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - Kansas City
mi
from
Kansas City, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Southwest Medical Center
mi
from
Liberal, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Southwest Medical Center
mi
from
Liberal, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Associates in Womens Health, PA - North Review
mi
from
Wichita, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Associates in Womens Health, PA - North Review
mi
from
Wichita, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Wichita
mi
from
Wichita, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Markey Cancer Center at University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Markey Cancer Center at University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Research Center at Boston Medical Center
mi
from
Boston, MA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Research Center at Boston Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Battle Creek Health System Cancer Care Center
mi
from
Battle Creek, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Battle Creek Health System Cancer Care Center
mi
from
Battle Creek, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Bay Regional Medical Center
mi
from
Bay City, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Bay Regional Medical Center
mi
from
Bay City, MI
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Mecosta County Medical Center
mi
from
Big Rapids, MI
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Mecosta County Medical Center
mi
from
Big Rapids, MI
Click here to add this to my saved trials